Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms LUTE
- Sponsors Genentech
- 30 Mar 2019 This trial has been completed in Slovakia, according to European Clinical Trials Database.
- 25 Feb 2019 Results of post-hoc analysis assessing stability of eosinophil levels from four studies (LUTE, VERSE, LAVOLTA I and LAVOLTA II) presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 18 May 2016 Results (pooled analysis of this and other two studies) assessing correlation between the change in these pharmacodynamics biomarkers and the change in FEV1 presented at the 112th International Conference of the American Thoracic Society.